Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Break Above 200-Day Moving Average - Time to Sell?

Key Points

• Cumberland Pharmaceuticals shares rose above their 200-day moving average, reaching $7.30 before closing at $6.70, compared with the long-term average of $6.15.
• Despite the technical breakout, the company maintains a consensus “Sell” rating, including a reissued “sell (D-)” rating from Weiss Ratings.
• Cumberland reported weak quarterly results, with an adjusted loss of $0.20 per share versus the expected $0.13 loss and revenue of just $0.17 million against an $8.50 million estimate.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.15 and traded as high as $7.30. Cumberland Pharmaceuticals shares last traded at $6.70, with a volume of 90,046 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Cumberland Pharmaceuticals has a consensus rating of "Sell".

Cumberland Pharmaceuticals Stock Performance

The stock has a market capitalization of $100.37 million, a price-to-earnings ratio of -9.44 and a beta of 0.06. The firm has a fifty day moving average of $7.37 and a 200-day moving average of $6.15.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The company had revenue of $0.17 million during the quarter, compared to analysts' expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several hedge funds have recently modified their holdings of CPIX. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company's stock worth $898,000 after buying an additional 4,081 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals in the 1st quarter worth $66,000. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals in the 2nd quarter worth $379,000. Finally, BlackRock Inc. acquired a new position in Cumberland Pharmaceuticals in the 2nd quarter worth $412,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company headquartered in Nashville, Tennessee. Founded in 1999, the company develops, acquires, and commercializes branded prescription products, with an emphasis on hospital acute care, gastroenterology, and other specialty areas.

Its portfolio has included Caldolor, an intravenous formulation of ibuprofen used for pain and fever; Vaprisol, an injectable treatment for certain cases of hyponatremia; Kristalose, a prescription form of lactulose used to treat constipation; and Omeclamox-Pak, a therapy for Helicobacter pylori infection and associated ulcer disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.